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two strategies from observational registry data of over 180,000
patients from the American College of Cardiology Foundation
(ACCF) and the Society of Thoracic Surgeons (STS) Database
Collaboration (ASCERT study). This study included medicare
patients who were 65 years or older with stable multi-vessel
coronary artery disease and underwent a revascularization
procedure between January 2004 and December 2007 in U.S.
As expected, two groups had significant differences at
baseline. PCI group hadmore females and older patientswhile
CABG group had more patients with heart failure, diabetes,
hypertension, chronic lung disease, cerebrovascular disease,
history of smoking, or peripheral arterial disease. PCI group
patients had higher ejection fraction despite having history of
more acute coronary syndromes. Triple vessel disease was
more in CABG group and double vessel disease was more in
PCI group. In the PCI group, 78% received drug-eluting stents,
16% received bare metal stent and 6% had procedure without
any stent. These groups were adjusted using inverse proba-
bility weighting and after adjustment all clinical covariates
were well balanced. One year after the procedure, there was
no significant difference in the mortality between the CABG
and PCI groups (6.2% and 6.8% respectively). At 4 years,
however, CABG demonstrated a significantly lower adjusted
mortality than PCI (16.4% vs. 20.8%; risk ratio, 0.79; 95% CI,
0.76e0.82). The benefit of CABG was present across all
subgroups like age, diabetes, renal dysfunction, etc.
Major limitation of this study, as discussed by authors
and the accompanying editorial is the effect of unmeasured
confounders. Treatment selection usually involves a careful
clinical judgement that goes beyond statistical calculations
and a few measured variables. Adequate control of
confounders may not be possible in this kind of non-
randomized comparison and thus affecting the reliability
of the results. Another limitation is bias in the selection
of revascularization procedure as evident by the huge
difference in the unadjusted baseline characteristics of the
two groups. Various important clinical variables were not
reported in the databases such as, bleeding risk, stroke rate,
drug compliance, angiogram and completeness of revascu-
larization procedure.Perspective
In various clinical trials comparing the two revascularization
strategies, mortality advantage for CABG has been found in
some studies for patients with diabetes and complex coronary
artery disease. Themost contemporary SYNTAX trial provides
a comprehensive SYNTAX score to access the extent and
complexity of the coronary artery disease and is a useful tool
in decision making for the choice of revascularization
strategy. More light on this issue is expected from the recently
concluded FREEDOM trial that has studied the two strategies
in diabetic multi-vessel disease. Results of this trial are
expected later this year in the annual AHA meeting. One
important aspect that has not been addressed in the ASCERT
study is the impact of optimal medical therapy. As shown in
the COURAGE trial, optimal medical therapy is at least as good
as PCI in mortality reduction for patients with stable coronaryartery disease. Scientific advancements has not only resulted
in better revascularization strategies over the time but has
also contributed significantly to the medical management of
coronary artery disease. A more contemporary answer to this
debate is expected from the proposed ISCHEMIA trial which
will compare angiography and revascularization plus optimal
medical therapy with the conservative strategy of optimal
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Objectives: This study investigated the effect of catheter-
based renal sympathetic denervation (RD) on left ventricular
hypertrophy (LVH) and systolic and diastolic function in
patients with resistant hypertension.
Background: LVH and diastolic dysfunction are associated
with elevated sympathetic activity and increased morbidity
and mortality. The effect of RD on LVH and LV function is
unclear.
Methods: Forty-six patients underwent bilateral RD, and 18
patients served as controls. Transthoracic echocardiography
was performed at baseline, and after 1 month and 6 months.
Results: Besides significant reduction of systolic and dia-
stolic blood pressure at 1 month and 6 months, RD signifi-
cantly reduced mean interventricular septum thickness from
14.1  1.9 mm to 13.4  2.1 mm and 12.5  1.4 mm (p ¼ 0.007),
and LVmass index from 53.9  15.6 g/m2 (112.4 33.9 g/m2) to
47.0  14.2 g/m2 (103.6  30.5 g/m2) and 44.7  14.9 g/m2
(94.9  29.8 g/m2) (p < 0.001) at 1 month and 6 months,
respectively. The mitral valve lateral E/E’ decreased after RD
from 9.9  4.0 to 7.9  2.2 at 1 month and 7.4  2.7 at 6 months
(p < 0.001), indicating reduction of LV filling pressures. Iso-
volumic relaxation time shortened (baseline 109.1  21.7 ms
vs. 85.6  24.4 ms at 6 months, p < 0.006), whereas ejection
fraction significantly increased after RD (baseline: 63.1  8.1%
vs. 70.1 11.5% at 6 months, p< 0.001). No significant changes
were obtained in control patients.
Conclusions: Besides the known effect on blood pressure,
our study showed for the first time that RD significantly
reduces LV mass and improves diastolic function, which
might have important prognostic implications in patients
with resistant hypertension at high cardiovascular risk.Perspective
Chronic activation of the sympathetic nervous system is
involved in the development and maintenance of arterial
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 4 2 7e4 3 4432hypertension. Moreover, sympathetic overactivity is a key
component of the signaling pathways altered in
hypertension-related cardiac remodeling. However, in the
LIFE study and other related meta-analysis, antihypertensive
treatment with beta blocker-based therapy resulted in less
LVH regression than an ACEI or ARB-based strategy. The
diminished efficacy of beta-blockers on LVH reduction might
reside in their inability to decrease myocardial fibrosis. In
contrast, RD strategy has shown significant LVH regression
and improvement of diastolic function. It has also been noted
that RD-induced LVH regression was not exclusively associ-
ated with BP reduction.
However, the number of patients involved in this trial was
small and the follow up duration was only 6 months.
Furthermore, no comparator therapy was available for this
group of resistant hypertension patients. A role for the
sympathetic nervous system in long-term control of body
fluid volumes and arterial pressure is controversial for several
reasons, including the difficulty in assessing the functional
effects of the renal nerves under chronic conditions. A key
issue with this RF energy denervation approach is whether
anatomical and/or functional re-growth of renal sympathetic
nerves occur, abrogating the long term BP-lowering benefits.
Such re-growth has been observed in other conditions where
sympathetic nerves have been disrupted, such as in organ
transplantation. A large randomized controlled trial with
long-term follow up is required.
ALTITUDE halted: Adverse events when aliskiren added toACEI, ARB therapy.
ALTITUDE study
Background: Patientswith type 2 diabetes are at increased risk
of macro- and microvascular disease, and the presence of
albuminuria and/or reduced kidney function further
enhances macrovascular risk. ACEI reduce both macro- and
microvascular events, yet the residual renal and cardiovas-
cular risk still remains high. Aliskiren a novel oral direct renin
inhibitor that unlike ACEI and ARBs, lowers plasma renin
activity, angiotensin I and angiotensin II levels, may thereby
provide greater benefit compared to ACEI or ARB alone.
Methods: The primary objective of the ALTITUDE trial was
to determine whether aliskiren 300 mg once daily, reduces
cardiovascular and renal morbidity and mortality compared
with placebo when added to conventional treatment
(including ACEI or ARB). ALTITUDE was an international,
randomized, double-blind, placebo-controlled, parallel-group
study, which included three categories of high-risk patients
with type 2 diabetes (aged 35 years): those with either
urinary albumin/creatinine ratio (UACR) 200 mg/g; micro-
albuminuria (UACR)20<200mg/g and eGFR30<60mL/min/
1.73 m2; and thirdly, those with a history of cardiovascular
disease and eGFR 30<60 mL/min/1.73 m2 with or without
microalbuminuria. ALTITUDE was an event driven trial that
aimed to randomize 8600 patients with a planned follow-up
time of 48 months. The primary outcome measure was time
to first event for the composite endpoint of cardiovasculardeath, resuscitated death, myocardial infarction, stroke,
unplanned hospitalization for heart failure, onset of end-stage
renal disease or doubling of baseline serum creatinine
concentration. Secondary endpoints included a composite CV
endpoint and a composite renal endpoint.
Perspective
The trial was prematurely halted by data safety and moni-
toring board (DSMB) as there was an increase in adverse
events and no apparent benefits among patients randomized
to aliskiren.
In making its recommendation, the DSMB noted that
the active-treatment group experienced an increased
incidence of nonfatal stroke, renal complications, hyper-
kalemia, and hypotension over 18e24 months of follow-up.
The committee concluded that patients were unlikely to
benefit from aliskiren on top of standard antihypertensive
therapy.
Though earlier this year, ACCELERATE trial looking at
aliskiren in combination with a calcium-channel blocker
showed positive results and the FDA had approved both
a dual- and triple-combination drug including aliskiren, but
the recommended combination did not include an ACEI or
ARB.
ALTITUDE study tried to evaluate the effect of direct
renin inhibition in diabetic patients who are likely to
experience the compensatory rise in plasma renin and
other downstream RAAS components, including aldoste-
rone, induced by ACEI or ARBs. The damaging impact of
aldosterone escape is well established in CVD and renal
disease during ACEI or ARB treatment. Aliskiren was
expected to block the compensatory rise in RAAS activity,
and offer a novel approach to dual blockade of the RAAS.
Although recent results of both VALIANT and ONTARGET
showed no clinical benefits of the combination of effective
doses of an ACEI and ARB, it was presumed combining
either of them with aliskiren would offset potential dele-
terious effects of compensating rennin activation. However,
the results of ALTITUDE study showed the combination to
be detrimental.
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Objectives: Does coronary artery calcification (CAC) in
patients with cardiac symptoms correlate with severity of
